Simulect

Company
Novartis

Approval Status
Approved May 1998

Treatment for
acute organ transplant rejection

Areas
Diabetes / Endocrinology , Immune System , Urology & Kidneys

Simulect has been approved for acute rejection episodes in renal transplant recipients.

Simulect works by blocking the receptor for IL-2, a protein that simulates proliferation of T-lymphocytes, which play a key role in organ transplant rejection.

Simulect Drug Information

The Simulect drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top